• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.

作者信息

Ungar Benjamin, Pavel Ana B, Li Randall, Kimmel Grace, Nia John, Hashim Peter, Kim Hee Jin, Chima Margot, Vekaria Anjali S, Estrada Yeriel, Xu Hui, Peng Xiangyu, Singer Giselle K, Baum Danielle, Mansouri Yasaman, Taliercio Mark, Guttman-Yassky Emma

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY; Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.

出版信息

J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16.

DOI:10.1016/j.jaci.2020.04.055
PMID:32428528
Abstract
摘要

相似文献

1
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.司库奇尤单抗靶向白细胞介素-17治疗特应性皮炎的2期随机双盲研究。
J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16.
2
Role of Th17 in the pathogenesis of cutaneous inflammatory diseases.Th17 在皮肤炎症性疾病发病机制中的作用。
J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):313-8.
3
Does mechanical scratching cause the recruitment of T-helper 17 cells in atopic dermatitis?机械搔抓会导致特应性皮炎中辅助性T细胞17的募集吗？
J Dermatol. 2019 Nov;46(11):e436-e437. doi: 10.1111/1346-8138.15011. Epub 2019 Jul 11.
4
The Role of Th17-Related Cytokines in Atopic Dermatitis.Th17 相关细胞因子在特应性皮炎中的作用。
Int J Mol Sci. 2020 Feb 15;21(4):1314. doi: 10.3390/ijms21041314.
5
Efficacy of biologics in atopic dermatitis.生物制剂在特应性皮炎中的疗效。
Expert Opin Biol Ther. 2020 May;20(5):525-538. doi: 10.1080/14712598.2020.1722998. Epub 2020 Feb 3.
6
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.CIM331 的首次临床试验，一种人源化抗人白细胞介素-31 受体 A 抗体，在健康志愿者和特应性皮炎患者中进行，以评估单次剂量的安全性、耐受性和药代动力学，采用随机、双盲、安慰剂对照研究。
Br J Dermatol. 2016 Feb;174(2):296-304. doi: 10.1111/bjd.14207. Epub 2015 Dec 19.
7
Therapeutic implications of IL-17A blockade in psoriasis.白细胞介素-17A阻断在银屑病中的治疗意义
Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:1-5. doi: 10.1016/S0001-7310(14)70012-2.
8
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.
9
Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis.抗白细胞介素-31受体A抗体治疗特应性皮炎
Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12490. Epub 2017 Apr 10.
10
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.中重度特应性皮炎伴重度瘙痒成人患者应用 nemolizumab 的 2B 期随机研究。
J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23.

引用本文的文献

1
Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches.特应性皮炎的治疗策略进展：新兴靶点与个性化方法
Biomolecules. 2025 Jun 8;15(6):838. doi: 10.3390/biom15060838.
2
Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review.利用特应性皮炎治疗反应生物标志物实现精准医学：我们目前进展如何？一篇叙述性综述。
Front Med (Lausanne). 2025 Apr 10;12:1574697. doi: 10.3389/fmed.2025.1574697. eCollection 2025.
3
Atopic dermatitis: pathogenesis and therapeutic intervention.
特应性皮炎：发病机制与治疗干预
MedComm (2020). 2024 Dec 8;5(12):e70029. doi: 10.1002/mco2.70029. eCollection 2024 Dec.
4
Biomarkers in Atopic Dermatitis.特应性皮炎中的生物标志物
Dermatol Ther (Heidelb). 2024 Jul;14(7):1729-1738. doi: 10.1007/s13555-024-01193-1. Epub 2024 Jun 14.
5
Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human.细胞因子在特应性皮炎病理生理学中的相互作用：来自小鼠模型和人类的见解。
Front Med (Lausanne). 2024 Mar 25;11:1342176. doi: 10.3389/fmed.2024.1342176. eCollection 2024.
6
The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis.特应性皮炎病程中瘙痒症生物治疗的疗效与效果
J Clin Med. 2024 Mar 18;13(6):1754. doi: 10.3390/jcm13061754.
7
Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives.解析特应性皮炎：对病理生理学、治疗进展及未来展望的见解
Cells. 2024 Feb 28;13(5):425. doi: 10.3390/cells13050425.
8
proteases trigger eosinophil-mediated skin inflammation.蛋白酶引发嗜酸性粒细胞介导的皮肤炎症。
Proc Natl Acad Sci U S A. 2024 Feb 6;121(6):e2309243121. doi: 10.1073/pnas.2309243121. Epub 2024 Jan 30.
9
Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis.在屋尘螨触发特应性皮炎的体外模型中，抑制白细胞介素-17 可改善角质形成细胞来源细胞因子的反应。
Sci Rep. 2023 Oct 3;13(1):16628. doi: 10.1038/s41598-023-42595-z.
10
Clinical trials of antibody drugs in the treatments of atopic dermatitis.抗体药物治疗特应性皮炎的临床试验。
Front Med (Lausanne). 2023 Sep 4;10:1229539. doi: 10.3389/fmed.2023.1229539. eCollection 2023.